Cognition Therapeutics Inc. Reports FDA Feedback After May Meeting

What Happened Cognition Therapeutics, Inc. (CGTX) filed a Form 8-K on June 24, 2026 (Item 8.01) to announce that it received written feedback from the U.S. Food and Drug Administration after a meeting the company held with the FDA in May 2026. The company issued a press release about the FDA feedback, and that press release is furnished as Exhibit 99.1 to the 8-K.

Key Details

• Filing date: June 24, 2026 (Current Report on Form 8-K, Item 8.01 Other Events).
• Event referenced: Written feedback from the FDA following a May 2026 meeting.
• Company action: Press release issued and filed as Exhibit 99.1 to the 8-K.
• Ticker: Cognition Therapeutics, Inc. (CGTX).

Why It Matters This is a regulatory update — written FDA feedback can affect the company’s clinical or regulatory plans and timing. The 8-K does not disclose the content of the feedback, so investors should view this as a sign that the company is engaged with the FDA and watch for follow-up announcements that describe any specific guidance, next steps, or impacts on development timelines.